Biotechnology Innovation Organization (BIO)
1225 Eye Street, NW
Suite 400
Washington
D.C.
20005-5958
United States
Tel: 202-962-9200
Fax: 202-962-9201
Website: http://www.bio.org/
Email: info@bio.org
About Biotechnology Innovation Organization (BIO)
The Biotechnology Innovation Organization (BIO) is the largest trade organization to serve and represent the emerging biotechnology industry in the United States and around the globe. The organization's leadership and service-oriented guidance have helped advance the industry and bring the benefits of biotechnology to the people of the world.
As the leading voice for the biotechnology industry, BIO represents companies of all sizes engaged in the development of products and services in the areas of agriculture, biomedicine, diagnostics, food, energy and environmental applications. Though biotechnology's future is bright, the industry's success will depend on the commitment, energy and direction of the group that helps guide its growth. BIO is a vital forum and an invaluable focal point to bring together the resources and expertise to meet critical challenges and serve the needs of its members.
3287 articles with Biotechnology Innovation Organization (BIO)
-
Influential CEO Jamie Dimon to Deliver Keynote at BIO 2019
4/30/2019
JPMorgan Chase & Co. Chairman and CEO will talk leadership, risk-taking and healthcare
-
The Biotechnology Innovation Organization (BIO) announced on April 16 that it was implementing a program to improve gender, racial, ethnic and LGBTQ diversity on the boards of directors, executive suites and functional leadership positions in the biopharma industry.
-
The California life Sciences Institutes (CLSI) recently named the winners of the 2019 Amgen Bay Area BioGENEius Challenge. This challenge is a Bay Area competition for high school students that focuses on the students’ individual research projects in the life sciences.Lori Lindburg, president and...
-
Biotechnology Industry Takes Action to Diversify Leadership
4/16/2019
BIO Launches Nationwide Campaign to Create Change
-
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
-
As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.
-
BIO Statement on President’s Proposed 2020 Budget
3/11/2019
Biotechnology Innovation Organization President and CEO Jim Greenwood issued the following statement regarding President Trump’s FY 2020 budget proposal
-
BIO Announces Partnership with Taiwan BIO for 2019 Conference and Exhibition
2/20/2019
The Biotechnology Innovation Organization (BIO) announced today it will join the Taiwan Bio-Industry Organization (Taiwan BIO) to host BIO Asia-Taiwan from July 24-28 in Taipei, Taiwan.
-
There is a concept held dear by many that there is strength in diversity. At South San Francisco-based Genentech, that is a concept also embraced by Sara Kenkare-Mitra, senior vice president of development sciences.
-
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
-
BIO Statement on the State of the Union
2/6/2019
"There is too much at stake for our elected leaders to place short-term political interests ahead of the long-term well-being of America's patients."
-
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
-
BIO Statement on New Proposal for Lowering Out-of-Pocket Costs for Medicines
2/1/2019
BIO’s President and CEO Jim Greenwood issued the following statement today after the Trump administration released a proposed rule that would alter safe harbor policies under the federal anti-kickback statute:
-
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
-
According to U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, less than two percent of Americans use biologics, but they account for 40 percent of total spending on prescription drugs.
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
BIO Statement on Hatch-Waxman Integrity Act of 2018
12/14/2018
Biotechnology Innovation Organization, President & CEO James C. Greenwood issued a statement on the Hatch-Waxman Integrity Act of 2018
-
BIO Applauds Bipartisan 2018 Farm Bill
12/11/2018
Bill includes key provisions that foster biotech innovation; support rural communities; and strengthen America’s bio-based economy
-
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
-
BIO Applauds Inclusion of Pro-Growth Provisions in Tax and Oversight Legislation
11/28/2018
This week, the House of Representatives plans to take up a tax and oversight package (H.R. 88) which includes a provision that would protect investments in start-ups from inadvertently triggering the net operating loss (NOL) limitations under Section 382 of the tax code.